PNOC

Kazia announces presentation of new data at AACR Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
PNOC, Patient, MD, Outline, AACR, KZIA, Therapy, Medical imaging

SYDNEY, March 13, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.

Key Points: 
  • SYDNEY, March 13, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.
  • There will be three presentations in total at AACR, including data from the phase 1 study of EVT801 in advanced solid cancers.
  • The data being presented will outline initial clinical data from the phase 1 study and provides support and direction for the next stage of the study.
  • In addition, data will be presented on the results of the combination therapy of paxalisib and gemcitabine for patients with relapsed/recurrent atypical teratoid/rhabdoid tumors AT/RT.

Lancaster Colony Reports Second Quarter Sales and Earnings

Retrieved on: 
Thursday, February 1, 2024
Organic Food, Retail, Restaurant, Bar, Manufacturing, Specialty, Other Manufacturing, Food, Beverage, Partial, PNOC, Consolidated, Webcast, ERP, Bakery, LANC

Lancaster Colony Corporation (Nasdaq: LANC) today reported results for the company’s fiscal second quarter ended December 31, 2023.

Key Points: 
  • Lancaster Colony Corporation (Nasdaq: LANC) today reported results for the company’s fiscal second quarter ended December 31, 2023.
  • Consolidated net sales increased 1.8% to a second quarter record $485.9 million versus $477.4 million last year.
  • Retail net sales grew 2.0% to $264.0 million while Foodservice net sales advanced 1.5% to $221.9 million.
  • Consolidated operating income increased $14.4 million, or 28.1%, to a second quarter record $65.8 million.

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Retrieved on: 
Wednesday, November 15, 2023
DRD2, Annual general meeting, Therapy, Eosinophilia, Disulfiram-like drug, Lymphocyte, Patient, KZIA, PNOC, Colitis, Mucositis, MD, Trial of the century, Diagnosis, DMG, Hyperglycemia, ONC201, Physician, OS, Society, Hypokalemia, DMG interpersonal, Pharmaceutical industry

The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.

Key Points: 
  • The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.
  • Sixty-eight children and young adults with DMG who completed standard of care radiation treatment received paxalisib (an investigational PI3K-mTOR dual inhibitor) and ONC201 (an investigational dopamine receptor D2 (DRD2) and ClpP agonist).
  • The abstract reported that median overall survival (OS) from time of diagnosis was 16.5 months.
  • "The PNOC022 study has exceeded expectations in terms of enrolment rates and has partnered with 29 leading children's cancer centers and physicians across the globe."

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Retrieved on: 
Friday, September 29, 2023
Society, Education, SNO, EST, Diffuse intrinsic pontine glioma, Pakistan Society of Neuro-Oncology, Research, KZIA, DIPG, Annual general meeting, PNOC, Health, DMG Mori Aktiengesellschaft, Pharmaceutical industry

SNO exists to advance multi-disciplinary brain tumour research, education, and collaboration to drive discovery and improve patient care.

Key Points: 
  • SNO exists to advance multi-disciplinary brain tumour research, education, and collaboration to drive discovery and improve patient care.
  • The 28th Annual Meeting of the Society for Neuro-Oncology will take place from November 15 - 19, 2023 in Vancouver, Canada.
  • Kazia Chief Executive Officer, Dr John Friend commented, "The Society for Neuro-Oncology conference is a high-profile meeting where many of the best ideas are discussed in brain tumour research.
  • We are very excited that the abstract from the PNOC022 study has been selected for oral presentation in this forum and look forward to sharing data with our shareholders and the market in due course."

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

Retrieved on: 
Thursday, May 25, 2023
White House, Disease, Radiation, Society, Drug development, GBM, Neuro-Oncology (journal), ONC201, Survival, American Association for Cancer Research, Research, Brain, Melanoma, Global Coalition Against Pneumonia, White, II, KZIA, DIPG, Patient, Cancer, Cancer Moonshot, Diagnosis, Diffuse intrinsic pontine glioma, PNOC, Oncology, FDA, Melanoma Research, Caregiver, Medical imaging, Glioblastoma, Kazia Pelka

SYDNEY, May 25, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, has been invited to the White House to participate in the Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) & Diffuse Intrinsic Pontine Glioma (DIPG), to be held on Thursday, 25 May 2023. 

Key Points: 
  • Kazia's CEO, Dr. John Friend, was invited and will be participating in this forum.
  • Friend to participate in the forum reflects the importance of Kazia's work in developing treatments for GBM and DIPG and reconfirms Kazia's position as a global leader in this field.
  • "We are honored to participate in the Cancer Moonshot forum on adult and pediatric brain cancer alongside global Neuro-Oncology thought leaders, researchers, US government officials and patient advocates," stated Dr.
  • GBM is the most aggressive and most common primary brain cancer with a five-year survival rate of approximately 10%.

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, May 4, 2023
AACR, University, Reiterate, Glioma, ONC201, Neoplasm, CNO, Survival, NDA, Biomarker, ID, Glioblastoma, Literature, American Association for Cancer Research, Patient, United Kingdom, PNOC, Research, ACTION, Conference, DRD2, Disease, Pharmaceutical industry

DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an operational update.
  • Research and development expenses decreased to $18.8 million for the first quarter of 2023, compared to $19.0 million for the same period in 2022.
  • General and administrative expenses increased to $5.7 million for the first quarter of 2023, compared to $5.6 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss first quarter 2023 financial results and provide a business update today at 8:30 a.m.

Star Gala inspires record-breaking donations to support life-saving resources for Children's Minnesota cancer and blood disorders program

Retrieved on: 
Monday, April 17, 2023
Hemoglobinopathy, KARE, TACL, International, Salt Lake City Union Pacific Depot, Registry, Neoplasm, Star Gala, International Ovarian Tumor Analysis trial, Cancer, Research, Brain, Hospital, Patient, Sickle cell disease, Diagnosis, PNOC, Minneapolis–Saint Paul, Pharmaceutical industry, Medical device, Child

The 31st annual Star Gala benefited the Children's Minnesota cancer and blood disorders program, the largest program of its kind in the Upper Midwest.

Key Points: 
  • The 31st annual Star Gala benefited the Children's Minnesota cancer and blood disorders program, the largest program of its kind in the Upper Midwest.
  • "Our program offers advanced, individualized care for our patients because we know that not every cancer and blood disorder diagnosis is the same.
  • Their support of our program allows us to continue advancing the treatment of cancer and blood disorders and provide the highly specialized care that can get kids on the road to recovery."
  • In addition, Children's Minnesota is home to the International Ovarian and Testicular Stromal Tumor Registry and International Pleuropulmonary Blastoma/DICER1 Registry .

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 2, 2023
Patient, Pediatrics, University of California, San Francisco, Glioma, Doctor of Philosophy, PNOC, Glioblastoma, ONC201, Central nervous system, Progression-free survival, Human, University, CNS, Malignancy, Conference call, Conference, DRD2, Neurosurgery, HGG, Emergent, Neoplasm, Bangladesh Technical Education Board, IDMC, MD, Sale, NIH, Brain, ACTION, Research, Consortium, MAS, UCSF, Pharmaceutical industry, Medical imaging, Video game, Cryptocurrency, Neurology

DURHAM, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided an operational update.

Key Points: 
  • Following the monetization of TEMBEXA, we have a strong balance sheet to fully fund Chimerix into 2027, including through potential approval of ONC201.
  • “As we look to 2023, we are making tremendous progress and continuing our strong execution to advance ONC201 towards regulatory approval.
  • General and administrative expenses increased to $5.3 million for the fourth quarter of 2022, compared to $5.2 million for the same period in 2021.
  • Chimerix will host a conference call and live audio webcast to discuss fourth quarter and full-year 2022 financial results and provide a business update today at 8:30 a.m.

Sargento Foods Inc. Announces Promotions for Future Growth

Retrieved on: 
Tuesday, January 17, 2023
Balanced line, COVID, Cracker, Executive, Quality, Marketing, Cheese cracker, Strategic planning, Customer demand planning, Social marketing, History, Growth, PNOC, Ebru, CPD, Corporate social responsibility, Foodservice, Management, Ingredient

"I would like to congratulate the outstanding employees and members of the Sargento Family who have received promotions," said Louie Gentine, CEO of Sargento.

Key Points: 
  • "I would like to congratulate the outstanding employees and members of the Sargento Family who have received promotions," said Louie Gentine, CEO of Sargento.
  • Ebru joined the Sargento Family in 2012 and most recently served as Deputy General Counsel and Vice President, Compliance.
  • During his time at Sargento, Chris has been a key contributor to several of the historical core and new product growth initiatives.
  • Notably, his teams managed the launch of Balanced Breaks® Cheese & Crackers, one of the most successful product launches in Sargento history.

Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma

Retrieved on: 
Sunday, January 8, 2023
Human, Ageing, Anemia, Day One, Hope, RAF, CBR, ORR, PNOC, Neuro-Oncology (journal), Patient, Mutation, Glioma, Fatigue, BRAF, New Drug Application, Pharmaceutical industry, Medical imaging

Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023.

Key Points: 
  • Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023.
  • The primary endpoint of the FIREFLY-1 trial is overall response rate (ORR) by Response Assessment for Neuro-Oncology (RANO) criteria as assessed by blinded independent central review.
  • The trial is being conducted in collaboration with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and is designed to support the potential regulatory approval of tovorafenib.
  • The global, Phase 3, registrational FIREFLY-2/LOGGIC clinical trial is evaluating once-weekly monotherapy tovorafenib in newly-diagnosed patients with pLGG harboring a known activating RAF alteration.